Anafranil

Panic Disorder, Depression, Obsessive-Compulsive Disorder

Treatment

2 FDA approvals

20 Active Studies for Anafranil

What is Anafranil

Clomipramine

The Generic name of this drug

Treatment Summary

Clomipramine is a type of antidepressant drug used to treat mood disorders such as depression, obsessive-compulsive disorder, and schizophrenia. It is a tricyclic antidepressant (TCA) that works by increasing the levels of serotonin and norepinephrine in the brain. Common side effects of clomipramine include blurred vision, dry mouth, constipation, and urinary retention. It can also be used to treat conditions such as panic disorder, chronic pain, cataplexy, trichotillomania, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine

Anafranil

is the brand name

image of different drug pills on a surface

Anafranil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Anafranil

Clomipramine

1989

104

Approved as Treatment by the FDA

Clomipramine, also called Anafranil, is approved by the FDA for 2 uses like Obsessive Compulsive Disorder (OCD) and Obsessive-Compulsive Disorder .

Obsessive Compulsive Disorder (OCD)

Helps manage Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

Helps manage Obsessive Compulsive Disorder (OCD)

Effectiveness

How Anafranil Affects Patients

Clomipramine is a type of antidepressant that is believed to work by blocking the reabsorption of certain neurotransmitters, like norepinephrine and serotonin, in the brain. Although this process occurs quickly, it may take up to two weeks for a person to notice an improvement in their mood. It is also thought that clomipramine changes the sensitivity of certain receptors in the brain, which can help with emotions. In addition, clomipramine can help relieve different types of pain, particularly nerve-related pain.

How Anafranil works in the body

Clomipramine works by blocking the reuptake of serotonin and noradrenaline in the brain. It also blocks certain receptors, such as alpha-1 receptors, and reduces the activity of some proteins. These effects help to reduce pain, particularly chronic or neuropathic pain.

When to interrupt dosage

The proposed dosage of Anafranil is contingent upon the determined condition, including Obsessive-Compulsive Disorder, Depression and Panic Disorder. The measure of dosage fluctuates, in accordance with the delivery approach featured in the table below.

Condition

Dosage

Administration

Obsessive-Compulsive Disorder

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Panic Disorder

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Depression

25.0 mg, , 50.0 mg, 75.0 mg, 10.0 mg, 100.0 mg

Capsule, , Oral, Capsule - Oral, Tablet, Tablet - Oral

Warnings

Anafranil Contraindications

Condition

Risk Level

Notes

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Anafranil.

Common Anafranil Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Anagrelide.

Apixaban

Major

The metabolism of Apixaban can be decreased when combined with Clomipramine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Asenapine.

Anafranil Toxicity & Overdose Risk

Symptoms of Anafranil overdose can range from minor to severe, depending on how much was taken and the age of the person. Severe reactions can lead to irregular heart rhythms, dangerously low blood pressure, seizures, and loss of consciousness. In the U.S., two people have died from taking too much Anafranil. Common side effects of Anafranil include drowsiness, low blood pressure, blurry vision, dry mouth, constipation, difficulty urinating, standing dizziness, rapid heart rate, high blood pressure, changes in the heart's electrical activity, heart failure, memory problems, confusion and mania

image of a doctor in a lab doing drug, clinical research

Anafranil Novel Uses: Which Conditions Have a Clinical Trial Featuring Anafranil?

634 active clinical trials are underway to assess the potential of Anafranil for treating Panic Disorder, Obsessive-Compulsive Disorder and Depression.

Condition

Clinical Trials

Trial Phases

Obsessive-Compulsive Disorder

66 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1

Panic Disorder

13 Actively Recruiting

Not Applicable

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Anafranil Reviews: What are patients saying about Anafranil?

5

Patient Review

10/9/2013

Anafranil for Obsessive Compulsive Disorder

Within days of starting this medication, I noticed a decrease in my anxiety levels. I no longer felt the need to check and recheck things all the time, which was a huge relief. For me, it was effective at half the starting dose, and I'm only 105 pounds.

5

Patient Review

12/10/2016

Anafranil for Obsessive Compulsive Disorder

When I was first diagnosed with OCD and started taking this medication, it made a huge difference in my life. It helped me manage my symptoms and cravings, and I felt better overall.

5

Patient Review

6/26/2017

Anafranil for Panic Disorder

I used to suffer from panic attacks and emetophobia, but this treatment has really helped me. I'm so much better now and I can live my life without anxiety interfering all the time.

5

Patient Review

12/7/2013

Anafranil for Anxious

Abilify has done wonders for my bipolar disorder. I highly recommend it to anyone who struggles with similar issues.

5

Patient Review

7/1/2013

Anafranil for Obsessive Compulsive Disorder

This drug is WAY more effective for OCD than Zoloft or Luvox. I've also found it helpful for the aches and pains that come along with depression.

5

Patient Review

8/4/2019

Anafranil for Obsessive Compulsive Disorder

Anafranil has been a life-saver for me. I was prescribed several SSRIs and none of them helped with my depression or intrusive thoughts. Within two weeks of taking Anafranil, I stopped crying and it slowly helped with the thoughts as well.

5

Patient Review

4/22/2019

Anafranil for Anxious

This treatment was life-saving.

4.3

Patient Review

2/6/2015

Anafranil for Obsessive Compulsive Disorder

This medication helped me to control my obsessive thoughts and it's been a huge game-changer for me. However, I have unfortunately gained about 40 pounds since starting the treatment. If anyone has any suggestions of how to lose this weight, I would be very grateful!

3.7

Patient Review

10/23/2014

Anafranil for Obsessive Compulsive Disorder

I was on this medication for a long time, but I decided to try something else. Now that I've tapered off of it, I feel pretty bad. Not sure how long these withdrawal symptoms will last.

2.3

Patient Review

4/2/2022

Anafranil for Obsessive Compulsive Disorder

Unfortunately, this medication made my OCD worse. I was dealing with more intrusive thoughts and felt crazy as a result.

1.7

Patient Review

2/8/2014

Anafranil for Obsessive Compulsive Disorder

I've been taking this drug on and off for over 30 years. It always works great, but it can take a couple of months to really kick in. The side effects can be tough to deal with, but it's worth it in the end.

1.3

Patient Review

4/28/2018

Anafranil for Obsessive Compulsive Disorder

Anafranil was decent for depression, but it didn't help my OCD at all. Additionally, I experienced a racing heart while taking it and had to stop because it was really scary. Finally, it made me feel sedated even during the day.

1

Patient Review

3/29/2019

Anafranil for Obsessive Compulsive Disorder

I took this medication for years at various doses and it made me very unstable, nervous and agitated. I would suggest trying Luvox, Zoloft or any other SSRI before taking this one.

1

Patient Review

6/27/2013

Anafranil for Obsessive Compulsive Disorder

Unfortunately, this medication made me very ill. I had a range of negative side effects that were quite unpleasant.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about anafranil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Anafranil drug used for?

"Anafranil is a drug used to treat symptoms of OCD such as recurrent thoughts or feelings and repetitive actions. It is available in generic form."

Answered by AI

Does Anafranil make you sleepy?

"You may feel tired, dizzy, or drowsy, or have blurred vision when taking Anafranil. Be careful not to drink alcohol or take any pain relievers, sleeping pills, or antihistamines while you're taking this medicine."

Answered by AI

Is Anafranil good for anxiety?

"Clomipramine helps to control obsessive-compulsive disorder by reducing the duration and intensity of the symptoms, as well as the anxiety that accompanies them. It may be just as effective as imipramine for panic attacks."

Answered by AI

Does Anafranil make you gain weight?

"In these studies, more than a quarter of patients who were given Anafranil gained at least seven percent of their body weight, compared to only four percent of those given a placebo. Several patients' weight gain exceeded 25% of their original body weight."

Answered by AI

Clinical Trials for Anafranil

Image of NewYork-Presbyterian Hospital / Weill Cornell Medicine in New York, United States.

Exposure and Response Prevention Therapy for Obsessive-Compulsive Disorder

10 - 17
All Sexes
New York, NY

The goal of this clinical trial is to learn whether brain scan results can help predict and track changes in obsessive-compulsive disorder, or OCD, symptoms in children and teens ages 10 to 17 who receive Exposure and Response Prevention therapy, also called ERP. ERP is a type of therapy in which participants practice facing OCD-related fears while resisting rituals or compulsions. The main question this study aims to answer is: Can each participant's pattern of brain connections, measured with functional MRI brain scans, help predict and track weekly changes in OCD symptoms during and after a 14-week course of ERP, including during planned monthly booster sessions and additional booster sessions offered if symptoms worsen? All participants will receive ERP. There is no placebo and no comparison group. Participants will: * Complete screening, consent or assent, interviews, questionnaires, and MRI safety checks * Receive 14 weekly ERP sessions * Complete OCD symptom assessments and functional MRI brain scans before, during, and after ERP * Receive planned monthly ERP booster sessions after the 14 weekly sessions * Receive additional brief ERP booster sessions if OCD symptoms worsen during follow-up * Take part for up to about 62 weeks

Waitlist Available
Has No Placebo

NewYork-Presbyterian Hospital / Weill Cornell Medicine

Conor Liston, MD, PhD

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials
Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials
Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Have you considered Anafranil clinical trials?

We made a collection of clinical trials featuring Anafranil, we think they might fit your search criteria.
Go to Trials